Microbot Medical (MBOT) EBITDA (2010 - 2026)

Microbot Medical's EBITDA history runs 17 years deep, the most recent figure standing at -$4.3 million for Q1 2026.

• Quarterly EBITDA fell 43.0% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.0 million (down 30.83% YoY) and the FY2025 annual result came in at -$14.7 million, down 26.82% from the prior year.
• EBITDA was -$4.3 million for Q1 2026 at Microbot Medical, down from -$4.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$2.1 million in Q4 2023 and bottomed at -$4.3 million in Q1 2026.
• A 5-year average of -$3.2 million and a median of -$3.2 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA surged 34.77% — and 2024, when it slumped 65.86%.
• Microbot Medical's EBITDA stood at -$3.1 million in 2022, then jumped by 32.59% to -$2.1 million in 2023, then slumped by 65.86% to -$3.4 million in 2024, then fell by 20.64% to -$4.1 million in 2025, then slipped by 4.4% to -$4.3 million in 2026.
• Business Quant data shows MBOT's EBITDA at -$4.3 million in Q1 2026, -$4.1 million in Q4 2025, and -$3.9 million in Q3 2025.